SNCA and neoplasm: Knockdown of the Ptpn2 gene by CRISPR-Cas9 significantly enhances the anti-tumor efficacy of PD-1 inhibitors, a finding that provides a new idea for developing synergistic therapeutic strategies of immune checkpoint inhibitors combined with gene editing.